BioMarin's Vimizim gets FDA nod

• BioMarin's (BMRN -0.5%) Vimizim becomes the 2nd treatment for Morquio A syndrome approved by the FDA this week. The nod isn't a surprise after nearly getting a near-unanimous thumbs up at the Ad Com two months ago.
• Press release